BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod

In a historic breakthrough for targeted protein degradation, BMS has secured the first FDA approval for a CELMoD therapy with the clearance of Zenbexus (iberdomide), marking the first multiple myeloma approval driven directly by minimal residual disease as a surrogate endpoint.